Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VX-880

- PMLiVE

Leiden reassures on key role at Vertex

Reshma Kewalramani to be new CEO, but Leiden will retain portfolio

- PMLiVE

The Cystic Fibrosis Buyers’ Club

Patients versus Pharma: campaigners using direct action to fight for access

- PMLiVE

Vertex files cystic fibrosis triple therapy with FDA

A landmark for company - but pricing controversy awaits

- PMLiVE

Tiziana joins type 1 diabetes prevention field

Cites potential advantages

- PMLiVE

Type 1 diabetes prevention promise sends Provention Bio soaring

Remarkable results prompt firm to consider regulatory pathway

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

Vertex makes choice for all-important CF triple therapy

Promises to treat up to 90% of CF patients

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links